Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 35.3%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 41,200 shares, a decline of 35.3% from the August 31st total of 63,700 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 54,500 shares, the days-to-cover ratio is presently 0.8 days. Based on an average daily trading volume, of 54,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.0% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Up 2.3%

NASDAQ COEP opened at $17.00 on Friday. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average of $13.28 and a two-hundred day moving average of $10.67. The firm has a market capitalization of $81.94 million, a price-to-earnings ratio of -2.93 and a beta of -0.49. Coeptis Therapeutics has a 52 week low of $2.31 and a 52 week high of $19.19.

Coeptis Therapeutics (NASDAQ:COEP) last released its earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share for the quarter. The firm had revenue of $0.20 million during the quarter.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.